Skip to content | Change text size
 

Dr Michelle P McIntosh

Image of Dr Michelle P McIntosh

Senior Lecturer

BPharm(Hons) Monash University
GCHE Monash University
PhD Monash University

Telephone: +61 3 9903 9531
Fax: +61 3 9903 9583
Email: michelle.mcintosh@pharm.monash.edu.au

Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences

Research interests

  • Pulmonary drug delivery of antibiotics and assessment of pharmacokinetic and pharmacodynamic relationships
  • Evaluation of pulmonary drug delivery formulations for systemic delivery of peptides and proteins
  • Cyclodextrin enhanced drug delivery of poorly water soluble drugs
  • Pre-clinical evaluation of novel formulations and new drug candidates
  • Bioanalytical method development using LC/MS and HPLC

Education

  • Unit coordinator for VCP4031 (Pharmaceutics III) and VCP4092 (Drug Development)
  • VPS3081 (Biopharmaceutics) lecturer in pharmacokinetics, drug absorption, drug delivery, drug dissolution
  • PAC2232 (Drug Delivery) lecturer in pharmacokinetics, drug absorption, bioequivalence
  • VCP4031 (Pharmaceutics III) lecturer in applied pharmaceutics and drug delivery

Representative publications

  1. Morton DAV, McIntosh MP, Sou T. Investigating effects of surface modifications on a mannitol dry powder inhaler plume by laser diffraction. Respiratory Drug Delivery. Editors R N Dalby, P R Byron, J Peart, J D Suman, S J Farr, P M Young, Publisher: Davis Healthcare International. 2008; 649.
  2. McIntosh MP, Carlson BJ, Schorno KS, Rajewski RA. Single quadrupole mass spectrometry for pre-clinical pharmacokinetic analysis: Quantitation of carvedilol in dog plasma. Journal of Chromatography B. 2007; 852:665-668.
  3. McIntosh MP, Narita H, Kameyama Y, Rajewski RA, Goto H. Evaluation of hemodynamic and sympathetic nerve activity in rabbits following administration of etomidate formulated in either a co-solvent vehicle or a sulfobutyl-ether cyclodextrin solution. Veterinary Anaesthesia and Analgesia. 2007; 34(3):149-156, 2007.
  4. Lucas AN, Tanol M, McIntosh MP, Rajewski RA. Preparation and purification of desethylamiodarone hydrochloride. Synthetic Communications. 2006; 36:3371-3376.
  5. Yasuji T, Haslam J, Kajiyama A, McIntosh MP, Rajewski RA. Production of micron and submicron polymer-based composite particles by coacervate dissolution with supercritical carbon dioxide extraction. Journal of Pharmaceutical Sciences. 2005; 95:581-588.
  6. McIntosh MP, Schwarting N, Rajewski RA. In vitro and In vivo evaluation of a sulfobuytl ether b-cyclodextrin enabled etomidate formulation. Journal of Pharmaceutical Sciences. 2004; 93:2585-2594.
  7. McIntosh MP, Charman WN, Campbell M, Porter CJH. Influence of physicochemical properties on the patterns of association of a series of aliphatic esters of halofantrine with plasma lipoproteins. Journal of Controlled Release. 2004; 95:275-289.
  8. McIntosh MP, Batey AJ, Coker SJ, Porter CJH, Charman WN. Evaluation of the impact of altered lipoprotein binding conditions on halofantrine induced QTc interval prolongation in an anaesthetized rabbit model. Journal of Pharmacy and Pharmacology. 2004; 56:69-77.
  9. McIntosh MP, Batey AJ, Porter CJH, Charman WN, Coker SJ. Desbutylhalofantrine: Evaluation of QT prolongation and other cardiovascular effects after intravenous administration in vivo. Journal of Cardiovascular Pharmacology. 2003 41:406-413.
  10. McIntosh MP, Rajewski RA. A simple and efficient high-performance liquid chromatographic assay for the quantitation of etomidate in plasma. Journal of Pharmaceutical and Biomedical Analysis. 2001; 24(4):689-693, 2001. 
  11. Wasan KM, Ramaswamy M, McIntosh MP, Porter CJH, Charman WN. Differences in the lipoprotein distribution of halofantrine are regulated by lipoprotein apolar lipid and protein concentration and lipid transfer protein 1 activity: In vitro studies in normolipidemic and dyslipidemic human plasmas. Journal of Pharmaceutical Sciences. 1999; 88(2):185-190.
  12. McIntosh MP, Porter CJH, Wasan KM, Ramaswamy M, Charman WN. Differences in the lipoprotein binding profiles of halofantrine in fed and fasted human and beagle plasma are dictated by the respective masses of apolar lipid in the lipoprotein core. Journal of Pharmaceutical Sciences. 1999; 88(3):378-384.

External appointments

  • Adjunct Assistant Professor, Department of Pharmaceutical Chemistry, University of Kansas